Insider Transactions in Q1 2024 at Dyne Therapeutics, Inc. (DYN)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 22
2024
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
119,360
-1.8%
|
$2,625,920
$22.66 P/Share
|
|
Feb 22
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Direct |
119,360
-1.8%
|
$2,625,920
$22.66 P/Share
|
|
Feb 21
2024
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
184,501
-1.36%
|
$4,059,022
$22.79 P/Share
|
|
Feb 21
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Direct |
184,501
-1.36%
|
$4,059,022
$22.79 P/Share
|
|
Feb 20
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Direct |
169,539
-1.21%
|
$3,899,397
$23.05 P/Share
|
|
Feb 20
2024
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
169,539
-1.21%
|
$3,899,397
$23.05 P/Share
|
|
Feb 16
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Direct |
162,707
-2.28%
|
$3,742,261
$23.14 P/Share
|
|
Feb 16
2024
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
162,707
-2.28%
|
$3,742,261
$23.14 P/Share
|
|
Feb 15
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Direct |
177,906
-1.21%
|
$4,269,744
$24.17 P/Share
|
|
Feb 15
2024
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
177,906
-1.21%
|
$4,269,744
$24.17 P/Share
|
|
Feb 12
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,493
-3.25%
|
$137,325
$25.07 P/Share
|
|
Jan 29
2024
|
Joshua T Brumm CEO & President |
SELL
Bona fide gift
|
Direct |
21,500
-1.84%
|
-
|
|
Jan 26
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100
-0.06%
|
$2,500
$25.0 P/Share
|
|
Jan 26
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
13,000
-9.47%
|
$312,000
$24.34 P/Share
|
|
Jan 26
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
13,000
+8.65%
|
$13,000
$1.03 P/Share
|
|
Jan 26
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
20,000
-6.12%
|
$480,000
$24.83 P/Share
|
|
Jan 26
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+10.89%
|
$0
$0.73 P/Share
|
|
Jan 09
2024
|
Dirk Kersten |
BUY
Open market or private purchase
|
Indirect |
1,714,285
+27.13%
|
$29,142,845
$17.5 P/Share
|
|
Jan 04
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
218,536
-14.29%
|
$3,933,648
$18.72 P/Share
|
|
Jan 04
2024
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
218,536
+11.46%
|
$655,608
$3.29 P/Share
|
|
Jan 04
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,009
-1.38%
|
$36,162
$18.04 P/Share
|
|
Jan 04
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,009
+1.36%
|
$0
$0.73 P/Share
|
|
Jan 04
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
42,453
-21.31%
|
$764,154
$18.13 P/Share
|
|
Jan 04
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,674
+10.22%
|
$22,674
$1.03 P/Share
|
|
Jan 03
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
51,183
-2.76%
|
$972,477
$19.29 P/Share
|
|
Jan 03
2024
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
51,183
+7.45%
|
$51,183
$1.03 P/Share
|
|
Jan 03
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
13,000
-9.47%
|
$234,000
$18.81 P/Share
|
|
Jan 03
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
13,000
+8.65%
|
$13,000
$1.03 P/Share
|
|
Jan 03
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
17,991
-5.73%
|
$323,838
$18.69 P/Share
|
|
Jan 03
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,991
+10.02%
|
$0
$0.73 P/Share
|
|
Jan 03
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
45,326
-7.26%
|
$861,194
$19.3 P/Share
|
|
Jan 03
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,326
+16.96%
|
$45,326
$1.03 P/Share
|
|
Jan 02
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
11,900
-7.65%
|
$154,700
$13.1 P/Share
|